49
Participants
Start Date
November 13, 2017
Primary Completion Date
May 18, 2021
Study Completion Date
May 18, 2021
Cobimetinib
Cobimetinib will be administered as per the schedule specified in the respective arm.
Venetoclax
Venetoclax will be administered as per the schedule specified in the respective arm.
Atezolizumab
Atezolizumab will be administered as per the schedule specified in the respective arm.
Rigshospitalet; Hæmatologisk Klinik, København Ø
Odense Universitetshospital, Odense C
Førde sentralsjukehus, Førde
Hospital Universitario de la Princesa, Madrid
Hospital Univ 12 de Octubre, Madrid
Clínica Universidad de Navarra, Pamplona
CHU - Hôtel Dieu hematolgie clinique, Nantes
Uni. der Johannes Gutenberg-Universitaet Mainz; III. Medizinische Klinik und Poliklinik, Mainz
UNI-Klinikum Heidelberg Medizinische Klinik Innere Medizin V, Heidelberg
CHU Lyon - Centre Hospitalier Lyon Sud, Pierre-Benite (Lyon)
Universitätsklinikum Tübingen Medizinische UNI-Klinik und Poliklinik Abt. Innere Medizin II, Tübingen
Hôpital Saint-Louis, Paris
Universtitätsklinikum Ulm; Klinik für Innere Medizin III, Ulm
IGR, Villejuif
Fakultni nemocnice Brno; Interni hematologicka a onkologicka klinika, Brno
Fakultni nemocnice Ostrava; Klinika hematoonkologie, Ostrava
Univerzita Karlova v Praze a Vseobecna fakultni nemocnice v Praze - 1; Lekarska Fakulta - I, Prague
Amsterdam UMC Location AMC, Amsterdam
Universitair Medisch Centrum Utrecht, Utrecht
Oslo University Hospital HF, Rikshospitalet, Oslo
Medical University School; Dept. of Haematology, Lodz
Uniwersytet Medyczny im.Karola Marcinkowskiego w Poznaniu, Późna
Centrum Onkologii - Inst.Im. Marii Sklodowskiej-Curie; Oncology, Warsaw
Hospital Universitari Germans Trias i Pujol; Servicio de Hematologia, Badalona
Hospital Clinic de Barcelona, Barcelona
Skånes Universitetssjukhus, Lund
Hoffmann-La Roche
INDUSTRY